Oppenheimer analyst Steven Lichtman maintained a Buy rating on Dexcom (DXCM) today. The company’s shares closed yesterday at $119.83.
According to TipRanks.com, Lichtman has 0 stars on 0-5 star ranking scale with an average return of -7.1% and a 46.7% success rate. Lichtman covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Motus Gi Holdings Inc.
Dexcom has an analyst consensus of Moderate Buy, with a price target consensus of $150.83, which is a 25.9% upside from current levels. In a report issued on November 7, Piper Jaffray also maintained a Buy rating on the stock with a $157 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $152.14 and a one-year low of $51.04. Currently, Dexcom has an average volume of 1.27M.
Based on the recent corporate insider activity of 105 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
DexCom, Inc. is a medical device manufacturing company, which engages in the design, development, and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes. Its products include Dexcom G4 PLATINUM System, Dexcom studio and Mobile apps.
